Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001224025 | SCV001396200 | pathogenic | DPAGT1-congenital disorder of glycosylation; Congenital myasthenic syndrome 13 | 2023-06-30 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects DPAGT1 function (PMID: 30388443). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DPAGT1 protein function. ClinVar contains an entry for this variant (Variation ID: 36919). This missense change has been observed in individual(s) with clinical features of congenital myasthenic syndrome and/or a congenital disorder of glycosylation (PMID: 22742743, 31153949; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs376039938, gnomAD 0.004%). This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 108 of the DPAGT1 protein (p.Met108Ile). |
Revvity Omics, |
RCV003144114 | SCV003831609 | likely pathogenic | not provided | 2022-06-10 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000030602 | SCV000053280 | pathogenic | Congenital myasthenic syndrome 13 | 2012-07-13 | no assertion criteria provided | literature only |